Tirabrutinib
- Generic Name
- Tirabrutinib
- Drug Type
- Small Molecule
- Chemical Formula
- C25H22N6O3
- CAS Number
- 1351636-18-4
- Unique Ingredient Identifier
- LXG44NDL2T
- Background
Tirabrutinib is under investigation in clinical trial NCT02626026 (Safety and Pharmacokinetics of GS-4059 in Healthy Volunteers and Subjects With Rheumatoid Arthritis (RA)).
Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104)
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Kyorin University
- Target Recruit Count
- 92
- Registration Number
- NCT06940791
- Locations
- 🇯🇵
Kyorin University Hospital, Tokyo, Japan
ONO-4059 Study in Patients With Steroid-resistant Pemphigus
- Conditions
- PemphigusSteroid-resistant Pemphigus
- Interventions
- Drug: ONO-4059 placebo
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 34
- Registration Number
- NCT06696716
- Locations
- 🇯🇵
Ichinomiya Municipal Hospital, Aichi, Japan
🇯🇵Nagoya City University Hospital, Aichi, Japan
🇯🇵Kurume University Hospital, Fukuoka, Japan
Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT06541665
- Locations
- 🇯🇵
Kindai University Hospital, Osakasayama-shi, Osaka, Japan
🇯🇵Institute of Science Tokyo Hospital, Bunkyo-ku, Tokyo, Japan
🇯🇵National Hospital Organization Disaster Medical Center, Midori-cho, Tokyo, Japan
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
- Conditions
- Primary CNS LymphomaRefractory Primary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 112
- Registration Number
- NCT04947319
- Locations
- 🇺🇸
University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States
🇺🇸Mayo Clinic- Phoenix, Phoenix, Arizona, United States
🇺🇸City of Hope Comprehensive Breast Cancer Center, Duarte, California, United States
Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT04827589
Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome
- Conditions
- Sjogren's Syndrome
- Interventions
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 152
- Registration Number
- NCT03100942
- Locations
- 🇺🇸
Clinical Research of West Florida, Inc., Clearwater, Florida, United States
🇺🇸Center for Rheumatology Immunology and Arthritis, Fort Lauderdale, Florida, United States
🇺🇸IRIS Research and Development, LLC, Plantation, Florida, United States
Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 36
- Registration Number
- NCT02983617
- Locations
- 🇩🇪
Evangelisches Diakoniekrankenhaus Bremen Hämatologie, Bremen, Germany
🇩🇪Universitätsklinikum Heidelberg, Abteilung Innere Medizin V, Heidelberg, Germany
🇩🇪Uniklinik Köln Klinik I für Innere Medizin, Köln, Germany
Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 35
- Registration Number
- NCT02968563
- Locations
- 🇩🇪
Ambulante Krebszentrum Schaubstraße, Frankfurt, Brandenburg, Germany
🇩🇪KH Maria Hilf-Franziskushaus, Mönchengladbach, Mönchengladbach, Germany
🇩🇪Klinikum Rechts der Isar der Technischen Universität München, München, Germany
Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 42
- Registration Number
- NCT02626026
- Locations
- 🇺🇸
Lovelace Scientific Resources, Inc., Venice, Florida, United States
🇺🇸Center for Arthritis & Osteoporosis, Elizabethtown, Kentucky, United States
🇺🇸Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 29
- Registration Number
- NCT02457559
- Locations
- 🇫🇷
Hopital Saint Eloi, Montpellier, France
🇫🇷Centre Hospitalier Lyon Sud, Pierre Benite, France
🇬🇧Leicester Royal Infirmary, Leicester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.